|Mr. John L. Erb||Chairman, CEO & Pres||588.9k||N/A||1949|
|Ms. Claudia Napal Drayton||Chief Financial Officer||411.44k||N/A||1968|
|Mr. Vitaliy Epshteyn||VP of Operations & Engineering||N/A||N/A||1978|
|Mr. Thomas P. Lynch||VP, Gen. Counsel, Chief Compliance Officer & Sec.||N/A||N/A||1967|
|Ms. Sandra Eayrs||VP of HR||N/A||N/A||N/A|
CHF Solutions, Inc., an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. It offers Aquadex FlexFlow consoles and the related disposable products in Singapore and Hong Kong. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.
CHF Solutions, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.